Cycloastragenol,
does it really help with Telomerase activation and telomere maintenance?
research showsIn a 117-person, one-year randomized trial, leukocyte telomere length increased relative to placebo in the low-dose TA-65 group, but the high-dose result was not significant and both the trial and early studies had substantial manufacturer support or involvement. A recent synthesis also found that telomere changes did not translate into functional improvement, resulting in C.
ads claimProduct descriptions may translate telomerase activation or leukocyte telomere changes into cellular renewal, reversal of biological age, or longevity. Published human data mainly concern the leukocyte telomere surrogate.
Useful facts when choosing a product
- TA-65 is a standardized branded cycloastragenol ingredient derived from Astragalus and is not interchangeable with generic Astragalus extract.
- The key RCT compared 250 U and 1,000 U for 12 months, with significance only at the low dose.
- Leukocyte telomere length can be influenced by shifts in immune-cell composition.
- Oncologic safety beyond 12 months remains insufficiently characterized.
Chamgap Semantic Classification Code
Candidate index · review held
UNK.cycloastragenol.UNK.telomerase-activation-and-telomere-maintenance.maintain.placeboUnknown > Cycloastragenol > Unknown > Telomerase activation and telomere maintenance > Maintenance claim > Placebo
An automated migration candidate, not an issued permanent code; exact claim scope remains under review. This machine-generated migration candidate helps retrieval but is not a permanent assignment. The original verdict ID and URL remain authoritative.
What the research actually shows
The 2011 study by Harley and colleagues observed participants in a paid health-maintenance program that included TA-65 and reported changes in the percentage of short telomeres and immune-cell markers, but it was not randomized and involved a multicomponent program. The 2016 RCT by Salvador and colleagues followed 117 relatively healthy cytomegalovirus-positive adults aged 53 to 87 for one year and reported increased telomere length with the 250 U low dose, while the 1,000 U high dose was not statistically significant; T.A. Sciences supported the study and authors had company ties. This trial assessed a telomere surrogate and did not establish functional aging benefits or longer lifespan.
Why this is classified as C (40)
Human randomized data and a telomere signal exist, but the endpoint is a surrogate, dose consistency is absent, industry involvement is substantial, and functional aging benefits are unestablished. Manufacturer concentration and the surrogate-endpoint rule support C with 40 points.
Counterpoint. An increase in telomere length remains in the low-dose arm using the exact TA-65 formulation. This judgment does not interpret that result as reversal of biological age or extension of lifespan.
Rejudgment record. Reassessment (cross-check reflected) — TA-65 has a telomere-length signal, but it is a surrogate, the positive low dose and null high dose reduce consistency, industry funding is concentrated, and functional aging outcomes are null, limiting the grade to C
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Maintenance of leukocyte telomere length | C | Industry-linked RCTs and a synthesis show a surrogate signal, but dose consistency and independent replication are limited. |
| Improved functional aging and longer lifespan | D | Functional frailty and inflammation were null in the synthesis, and no lifespan endpoint is available. |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Harley CB et al. 2011 | Nonrandomized observational health-maintenance program | 1 | TA Sciences and company-linked authors | Percentage of short leukocyte telomeres, immune cells, and laboratory markers | Some telomere and immune markers changed, but there was no control group and the program had multiple components. | Supportive |
| Salvador L et al. 2016 | Randomized double-blind placebo-controlled trial | 12 | Supported by T.A. Sciences with company employees and linked authors | Median and shortest-20% leukocyte telomere length | The 250 U group increased, while the 1,000 U group was not significant versus placebo. | Key |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-07-11).
Final verification and publication gate: Codex · Evidence date: 2026-07-11 · Corrections: none
Cite this verdict
[Chamgap] Cycloastragenol (TA-65) × Telomerase activation and telomere maintenance — Evidence Grade C·40. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/antioxidant-aging/cycloastragenol-ta65-telomeres/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.